Fulcrum Therapeutics Strengthens Board of Directors with Appointment of Kate Haviland

Cambridge, Mass., June 27, 2018 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced the appointment of Kate Haviland, Chief Business Officer of Blueprint Medicines, to its Board of Directors. 

Read More